Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies,
click here
. If you proceed browsing this website, you will be consenting to the use of all cookies.
More info
ita
eng
Our Group
Innovation & Research
Therapy and Wellness
Menarini News
Values
Careers
Home
Home
Innovation & Research
Publications
Pracinostat
MEN1703
MEN1611
MEN1112
MEN1309
Meropenem/Vaborbactam
Delafloxacin
Oritavancin
Clinical studies
clinical trials database
the research centres
Biotechnology
Publications
Publications Archive
2018 (7)
2017 (7)
2016 (10)
2015 (24)
2014 (28)
2013 (19)
2012 (15)
2011 (19)
2010 (20)
2009 (17)
2008 (18)
2007 (14)
2006 (23)
2005 (14)
2004 (24)
Delafloxacin: Activity against Fastidious Organisms Tested by EUCAST vs CLSI Methodology
asm microbe 2018 Atlanta June 7-11, 2018.
CD205-Shuttle Study: a first in human trial of Men1309/OBT076 an ADC targeting CD205 in solid tumor and NHL
Asco Annual Meeting 2018 Chicago June 1-5,2018
Translational model-based approach to the dose-range selection of an antibody-drug conjugate entering Phase I.
Page twenty-seventy meeting, 29 May-1June, 2018.
The role of MEN1611, a class I PI3-kinase (PI3K) inhibitor, in reprogramming the pro-tumoral inflammatory environment.
AACR Annual Meeting 2018, Chicago April 1-5,2018
MEN1611, a novel a-selective PI3K inhibitor in solid tumors
AACR Annual Meeting 2018, Chicago April 1-5,2018
Page 1 of 2
First
Previous
[1]
2
Next
Last
THERAPEUTIC AREAS
Discover all of Menarini's products marketed in Italy.
Read More »
DIAGNOSTICS
Advanced Technology
READ MORE »
THE MENARINI GROUP
Discover the leading Italian pharmaceutical company in the world.
Read More »
MENARINI PILLS OF ART
Concession granted by Italian Ministry for Cultural Heritage and Activities
Read more